Thomson Reuters Announces 2009 Edition Of The CMR International Pharmaceutical R&D Factbook

Factbook Provides Authoritative Industry Metrics For The Key Stages In Drug Development

Philadelphia, PA USA, London UK. — The 2009 edition of the trusted and often cited compendium of pharmaceutical research and development statistics, the CMR International Pharmaceutical R&D Factbook, is now available. This year’s Factbook offers extended content including patent information and emerging trends in worldwide pharmaceutical R&D.

“The R&D Factbook provides the data that R&D companies need to make informed decisions,” said Dr. Jane Sharples, General Manager of CMR International. “With this publication, R&D companies can gain insights into industry dynamics and trends, determine how they perform against the market as a whole and gauge their productivity in relation to their peers and competitors. Companies can also see the consequences of adopting different R&D strategies. In short, they have accurate, independent and validated information on which to base business decisions.”

Highlights of the 2009 edition include:

• The number of new molecular entities (NME) launched onto the global market failed to improve on 2008’s 20-year low. Actual development times for new molecular entities are slowly increasing to 14 years, though major pharmaceutical companies (those that spent more than $2 billion on R&D in 2008) take on average slightly more than 11 years.

• Anti-cancer therapy is the most common area for new patent filing on emerging targets.

• India leads the way in the recent trend towards new molecular entity research by generic specialty companies.

The Centre for Medicines Research International Ltd (CMR International), a Thomson Reuters business, yearly publishes the Factbook. This is an up-to-date business planning tool for decision makers in the pharmaceutical industry, including R&D, corporate finance, business strategy, marketing planning and corporate communications professionals. Since 1994, CMR International has worked with leading global pharmaceutical and biotechnology companies to assess R&D productivity and provide insights which help organizations to improve the planning and effectiveness of R&D.

The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 percent of the industry’s global R&D expenditure. The CMR International 2009 Pharmaceutical R&D Factbook is available as single-user or enterprise-wide editions, in either electronic or hard copy format.